Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Boehringer Ingelheim
McKesson
Moodys
AstraZeneca

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Drug Sales Trends for DIAZEPAM

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Payment Methods and Pharmacy Types for DIAZEPAM (2017)

Revenues by Pharmacy Type

Pharmacy Type Revenues
MAIL-ORDER $15,817,266
INSIDE ANOTHER STORE $14,679,555
[disabled in preview] $50,736,637
This preview shows a limited data set
Subscribe for full access, or try a Trial

Units Sold by Pharmacy Type

Pharmacy Type Units
MAIL-ORDER 649,520
INSIDE ANOTHER STORE 1,119,708
[disabled in preview] 3,352,019
This preview shows a limited data set
Subscribe for full access, or try a Trial

Revenues by Payment Method

Payment Method Revenues
MEDICAID $9,444,625
MEDICARE $27,013,730
[disabled in preview] $44,818,011
This preview shows a limited data set
Subscribe for full access, or try a Trial
Drug Sales Revenue Trends for DIAZEPAM
Drug Units Sold Trends for DIAZEPAM

Annual Sales Revenues and Units Sold for DIAZEPAM

These sales figures are drawn from a US national survey of drug expenditures
Drug Name Revenues (USD) Units Year
DIAZEPAM   Start Trial   Start Trial 2017
DIAZEPAM   Start Trial   Start Trial 2016
DIAZEPAM   Start Trial   Start Trial 2015
DIAZEPAM   Start Trial   Start Trial 2014
DIAZEPAM   Start Trial   Start Trial 2013
DIAZEPAM   Start Trial   Start Trial 2012
DIAZEPAM   Start Trial   Start Trial 2011
>Drug Name >Revenues (USD) >Units >Year

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Express Scripts
Boehringer Ingelheim
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
Copyright 2002-2020 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2020 - 2021
 NCE-1 Patent Challenge Dates 2020 - 2021
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2020, www.DrugPatentWatch.com.

Links

Follow DrugPatentWatch:

DrugPatentWatch reviews